Pain Reduction and Adverse Effects of Intravenous Metoclopramide for Acute Migraine Attack: A Systematic Review and Meta-analysis of Randomized-controlled Trials

Overview

Journal World J Methodol

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2022 Sep 26

PMID 36159095

Authors

Nat Ungrungseesopon

Wachira Wongtanasarasin

Affiliations

Soon will be listed here.

Abstract

Background: Metoclopramide may be used to treat people suffering from acute migraine. However, no comprehensive investigation on this issue has been recorded. This review will provide more solid evidence for the use of metoclopramide in treating acute migraine.

Aim: To compare the efficacy of intravenous metoclopramide with other therapies in migraine attack treatment in an emergency department (ED).

Methods: We included randomized controlled trials of participants older than 18 years with acute migraine headaches, which included at least one arm that received intravenous (IV) metoclopramide at the ED. A literature search of PubMed, Web of Science, Cochrane Collaboration, and Reference Citation Analysis on December 31, 2021 retrieved other drugs or placebo-controlled studies without language limitation. The risk of bias was assessed using the Cochrane risk of bias tool. The primary endpoint was pain reduction at 60 min or closest to 1 h after treatment, as measured by the pain scale. Secondary endpoints included adverse effects or reactions resulting from metoclopramide or comparisons.

Results: Fourteen trials with a total of 1661 individuals were eligible for review. The risk of bias ranged from low to intermediate. IV metoclopramide administration was not associated with higher pain reduction at 1 h (Standard mean difference [SMD] = -0.03, 95% confidence interval [CI]: -0.33-0.28, = 0.87). However, metoclopramide was associated with better pain reduction than placebo (SMD = 1.04, 95%CI: 0.50-1.58, = 0.0002). In addition, side effects were not significantly different between IV metoclopramide and other drugs or placebo (odds ratio [OR] = 0.76, 95%CI: 0.48-1.19, = 0.09 and OR = 0.92, 95%CI: 0.31-2.74, = 0.54, respectively).

Conclusion: Metoclopramide is more effective than placebo in treating migraine in the ED. Despite the observed tendency of decreased side effects, its effectiveness compared to other regimens is poorly understood. More research on this area is needed to treat migraine in acute care settings effectively.

Citing Articles

The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.

Abdelmonem H, Abdelhay H, Abdelwadoud G, Alhosini A, Ahmed A, Mohamed S BMC Neurol. 2023; 23(1):221.

PMID: 37291500 PMC: 10249175. DOI: 10.1186/s12883-023-03259-7.

References

Friedman B, Garber L, Yoon A, Solorzano C, Wollowitz A, Esses D . Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014; 82(11):976-83. DOI: 10.1212/WNL.0000000000000223. View

Coppola M, Yealy D, Leibold R . Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995; 26(5):541-6. DOI: 10.1016/s0196-0644(95)70001-3. View

Colman I, Brown M, Innes G, Grafstein E, Roberts T, Rowe B . Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004; 329(7479):1369-73. PMC: 535449. DOI: 10.1136/bmj.38281.595718.7C. View

Talabi S, Masoumi B, Azizkhani R, Esmailian M . Metoclopramide versus sumatriptan for treatment of migraine headache: A randomized clinical trial. J Res Med Sci. 2014; 18(8):695-8. PMC: 3872609. View

Gaffigan M, Bruner D, Wason C, Pritchard A, Frumkin K . A Randomized Controlled Trial of Intravenous Haloperidol vs. Intravenous Metoclopramide for Acute Migraine Therapy in the Emergency Department. J Emerg Med. 2015; 49(3):326-34. DOI: 10.1016/j.jemermed.2015.03.023. View

Friedman B, Hochberg M, Esses D, Grosberg B, Corbo J, Toosi B . Applying the International Classification of Headache Disorders to the emergency department: an assessment of reproducibility and the frequency with which a unique diagnosis can be assigned to every acute headache presentation. Ann Emerg Med. 2007; 49(4):409-19, 419.e1-9. DOI: 10.1016/j.annemergmed.2006.11.004. View

Eken C . Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis. Am J Emerg Med. 2015; 33(3):331-7. DOI: 10.1016/j.ajem.2014.11.013. View

Charles A . Migraine. N Engl J Med. 2017; 377(6):553-561. DOI: 10.1056/NEJMcp1605502. View

Amiri H, Ghodrati N, Nikuyeh M, Shams-Vahdati S, Jalilzadeh-Binazar M . Comparison of granisetron and metoclopramide in the treatment of pain and emesis in migraine patients: A randomized controlled trial study. Turk J Emerg Med. 2017; 17(2):61-64. PMC: 5459513. DOI: 10.1016/j.tjem.2016.12.004. View

10.

Najjar M, Hall T, Estupinan B . Metoclopramide for Acute Migraine Treatment in the Emergency Department: An Effective Alternative to Opioids. Cureus. 2017; 9(4):e1181. PMC: 5438233. DOI: 10.7759/cureus.1181. View

11.

Friedman B, Corbo J, Lipton R, Bijur P, Esses D, Solorzano C . A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005; 64(3):463-8. DOI: 10.1212/01.WNL.0000150904.28131.DD. View

12.

Yavuz E, Gulacti U, Lok U, Turgut K . Intravenous metoclopramide versus dexketoprofen trometamol versus metoclopramide+ dexketoprofen trometamol in acute migraine attack in the emergency department: A randomized double-blind controlled trial. Am J Emerg Med. 2020; 38(11):2254-2258. DOI: 10.1016/j.ajem.2020.04.038. View

13.

Saylor D, Steiner T . The Global Burden of Headache. Semin Neurol. 2018; 38(2):182-190. DOI: 10.1055/s-0038-1646946. View

14.

Ailani J, Burch R, Robbins M . The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021; 61(7):1021-1039. DOI: 10.1111/head.14153. View

15.

Steiner T, Stovner L, Jensen R, Uluduz D, Katsarava Z . Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020; 21(1):137. PMC: 7708887. DOI: 10.1186/s10194-020-01208-0. View

16.

Chalaupka F . Acute myocardial infarction with sumatriptan: a case report and review of the literature. Headache. 2009; 49(5):762-4. DOI: 10.1111/j.1526-4610.2009.01409.x. View

17.

Orr S, Friedman B, Christie S, Minen M, Bamford C, Kelley N . Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2016; 56(6):911-40. DOI: 10.1111/head.12835. View

18.

Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C . A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia. 2005; 25(3):199-204. DOI: 10.1111/j.1468-2982.2004.00840.x. View

19.

ELLIS G, Delaney J, DeHart D, Owens A . The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med. 1993; 22(2):191-5. DOI: 10.1016/s0196-0644(05)80201-x. View

20.

Cameron J, Lane P, Speechley M . Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med. 1995; 2(7):597-602. DOI: 10.1111/j.1553-2712.1995.tb03596.x. View